4-1±0 3 ,U/ml, though the plasma TSH level had become slightly raised in three.
de Deuxchaisnes and Krane, 1967) . Further evidence that there is no simple relation between prolonged hypophosphataemia and myopathy is found in the common Xlinked form of hereditary rickets, in which myopathy is always absent despite lifelong hypophosphataemia (Dent et al., 1973) .
Better understanding of these problems may result from recent observations that the metabolism of vitamin D is closely related to that of phosphate at cellular level. The production by kidney of 1:25-dihydroxycholecalciferol, the biologically active hormonal form of vitamin D, from 25-HCC (Fraser and Kodicek, 1970) may be regulated by intracellular phosphate concentration (Tanaka and De Luca, 1973) . If, as seems likely, vitamin D is proved to have a direct action on muscle, perhaps in controlling calcium ion transport across the sarcoplasmic reticulum (Curry et al., 1974) , as well as on intestine and bone it would not be surprising if this function were also regulated in part by the availability of phosphate. In patients receiving maintenance haemodialysis renal metabolism of vitamin D may be defective (Mawer et al., 1971 All of a group of 61 of the euthyroid patients with normal plasma TSH levels (4 0±0 2 ,uU/ml) in 1972 remained euthyroid at 24 months with a mean plasma TSH of Introduction The incidence of hypothyroidism after 131I treatment of thyrotoxicosis is greatest in the first year (7-22%) and continues at 2-4% a year (Hagen, 1968) . Toft et al. (1974) found a low serum thyroxine (T-4) level to be a sensitive index of developing hypothyroidism in the early months after radioiodine therapy but it has not yet proved possible, using conventional tests of thyroid function, to predict when or in whom hypothyroidism will occur in later years. This results in the follow-up of large numbers of patients. A high plasma thyrotrophin (TSH) level is considered to be a good index of thyroid failure but is not uncommon after 131I treatment of thyrotoxicosis and may persist in euthyroid patients for many months (Slingerland et al., 1972; Toft et al., 1973 The mean (± S.E.) serum T-4 and plasma TSH levels in the 69 euthyroid patients with high plasma TSH levels in 1972 and in those remaining euthyroid in 1973 and 1974, 15 and 24 months later, are shown in table I. Only three of the 69 patients developed hypothyroidism over the 15-month period; the plasma TSH had risen in one (from 34-6 to 67-3 ,U/ml), had fallen in the second (from 45-6 to 28-2 pU/ml), and had remained virtually unchanged in the third (90 4 and 92-8 ,uU/ml). At 24 months 64 of the 66 patients remaining euthyroid in 1973 were available for study. Hypothyroidism had developed in a further three patients in whom the plasma TSH levels remained essentially unchanged (32 8 and 32-0, 23-5 and 26-1, and 27-5 and 31-2 UI/ml). All 61 euthyroid patients with normal plasma TSH levels in 1972 remained euthyroid over a 24-month period and the mean serum T-4 and plasma TSH levels in 1972 and 1974 are shown in table II. In three of these 61 patients, however, the plasma TSH became slightly raised-9A4, 9 7, and 12-6 I±U/ml respectively. The mean serum T-4 level in the euthyroid patients with a high plasma TSH was significantly lower than that in the euthyroid patients with a normal plasma TSH both in 1972 (P <0 001) and in 1974 (P <0 001).
Discussion
The high incidence of hypothyroidism after 181I treatment of thyrotoxicosis necessitates the follow-up of large numbers of patients. In most centres patients are seen frequently in the first post-therapy year, when the incidence of hypothyroidism is highest, and at intervals of six to 12 months thereafter on a lifelong basis or until hypothyroidism develops. Though a low serum T-4 is a good index of impending hypothyroidism in the early months after radioiodine treatment (Toft et al., 1974) it has not proved possible to predict the onset of hypothyroidism in patients treated in earlier years. A low serum T4 does not have the same significance in such patients as it may persist indefinitely while the euthyroid state is maintained by high or normal levels of circulating triiodothyronine (Sterling et al., 1971; Bellabarba et al., 1972) . Over half (58%) of the patients treated with 1831 for thyrotoxicosis between 1954 and 1966 had high plasm TSH levels in Fzibruary 1972 when euthyroid. These high levels, onsidered to be a sensitive index of thyroid failure, remained unchanged over 24 months in most of the patients but hypothyroidism occurred at a rate of 5% a year. On the other hand, no patient in whom a normal plasma TSH level was found in February 1972, six to 18 years after radioiodine treatment, developed hypothyroidism over the same 24-month period.
It is suggested that in the long-term follow-up of patients treated with l81I for thyrotoxicosis those with a high plasma TSH level should be examined at yearly intervals as they are at risk of developing hypothyroidism, whereas those with a low plasma TSH level should be seen at intervals of two years or longer.
One possible interpretation of the significantly lower mean serum T-4 levels in the euthyroid patients with high plasma TSH levels compared with the euthyroid patients with normal plasma TSH levels after 13'I dherapy is tht the serum T4 levels in the former grop were subopimal. Any increse in morbidity, such as isch-aenic heart disease, in these patients will become apparent only in future years, and at present no thvroxine reolacement therapy has been instituted.
